アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
CSKRFRFDDSLPNPHE, corresponding to amino acids 351/365 of Human DRAK2. (Peptide available as ab8454.)
Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP,are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases) (1). DRAKs contain anN-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.
Our Abpromise guarantee covers the use of ab8419 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/1000. Detects a band of approximately 45 kDa (predicted molecular weight: 43 kDa).Can be blocked with Human DRAK2 peptide (ab8454).|
|ICC/IF||Use a concentration of 10 µg/ml.|
ab8419 at 10µg/ml staining DRAK2 in Jurkat cells by ICC/IF
ab8419 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"